Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly regimen (3 days on/4 days
Acrivon's cancer medicine (ACR-2316) moved into a bigger testing stage because early results showed it worked safely and helped patients stay healthy longer. When a medicine passes early tests smoothly, it hints the company might be on the right track, but lots of testing still lies ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.